TRYPF TRYP THERAPEUTICS INC
- 0.049000
- +0.002000+4.26%
TRYP THERAPEUTICS INC News
Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing
Tryp Therapeutics Inc. (OTCQB:TRYPF), a Canadian biotech leader in psychedelics, has officially received approval from Exopharm Limited shareholders for their strategic merger, paving the way for a ne
CSE Bulletin: Delist - Tryp Therapeutics Inc. (TRYP)
Toronto, Ontario--(Newsfile Corp. - Le 24 avril/April 2024) - Tryp Therapeutics Inc. (the "Issuer") has announced that further to the press release dated February 8, 2024, the shareholders of Exopharm
CSE Bulletin: Reinstatement - Tryp Therapeutics Inc. (TRYP)
Toronto, Ontario--(Newsfile Corp. - le 5 mars/March 2024) - Effective immediately, Tryp Therapeutics Inc. will be reinstated for trading. The Company has rectified the situation that gave rise to the
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for P
Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
Psychedelics biotech Tryp Therapeutics (OTCQB:TRYPF) is advancing its psilocybin-based portfolio through several recent milestones. Upcoming Phase 1 For IV Psilocin First, the company received approva
Tryp Therapeutics Signs of Definitive Agreement With Exopharm
Tryp Therapeutics Inc. Announces Signing of Definitive Agreement With Exopharm Limited
Each of the directors and executive officers of Tryp have entered into voting and support agreements with the Purchaser and have agreed to, among other things, vote their securities in favour of the Arrangement.
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000
KELOWNA, BC / ACCESSWIRE / November 20, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (t
Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000
KELOWNA, BC / ACCESSWIRE / October 11, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (th
Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer
KELOWNA, BC / ACCESSWIRE / August 3, 2023 / Tryp Therapeutics Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company dedicated to developing intravenous-infused
With Great Sadness Tryp Announces the Passing of David Tousley, Director
KELOWNA, BC / ACCESSWIRE / August 2, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), announces with deep regret the passing of Mr. David Tousley, Director of Tryp and
Psilocybin For IBS Gets FDA Nod To Begin Clinical Trials At Mass. General Hospital
Tryp Therapeutics' (OTCQB:TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital
Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital
KELOWNA, BC / ACCESSWIRE / July 13, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused p
Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
Developmental-stage psychedelics biotech Silo Pharma (NASDAQ:SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with fibromyalg
Tryp Submits IND Application To FDA For Clinical Trial Of Psilocybin-Assisted Psychotherapy In Patients With IBS
Tryp Therapeutics, Inc. (OTCQB:TRYPF) (CSE:TRYP) has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for its planned phase 2a clinical trial investigating th
Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital
KELOWNA, BC / ACCESSWIRE / May 24, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused ps
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued Oregon's 2020 measure legalizing psilocybin therapy within a regulated centers model is approaching actual imple
Tryp Therapeutics Secures $1.6M Via Oversubscribed Private Placement
Tryp Therapeutics Inc. (OTCQB:TRYPF) (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Secured Convertible Debentures for Gross Proceeds of AUD$2,400,000
KELOWNA, BC / ACCESSWIRE / April 27, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the
EXCLUSIVE: Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental
Analysis
Price Target
No Data
